Skip to main content
Equibles
IBIO logo

IBIO · iBio, Inc. · Investor Relations

Track IBIO — free

Use IBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.73 -0.03 (-4.00%) At close · Nov 13 Q4 2022 earnings call transcript
Rebalance outlook locked
Going-concern doubt — cleared Nov 10, 2026

The latest filing states the doubt was alleviated.

“Despite this liquidity position, the history of significant losses, the negative cash flow from operations, and the dependence by us on our ability to obtain additional financing to fund our operations raised substantial doubt in the past about our ability to continue as a going concern. However, based on our current liquidity we concluded the substantial doubt has been alleviated.”
View the 10-Q filed Nov 10, 2026
Market Cap
$51.55M
Shares
70.46M
Volume · Nov 13 463.73K Avg daily vol (3M) 696.5K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-12-01 14:30 UTC Piper Sandler 38th Annual Healthcare Conference Conference

Recent news

Date Headline
2026-11-10 iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
2026-11-02 iBio to Participate in Upcoming Investor Conferences
2026-10-13 iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
2026-08-28 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-08-04 iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
2026-07-01 iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
2026-05-12 iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-08 iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
2026-04-08 iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
2026-03-09 iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
2026-02-10 iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-01-12 iBio Announces $26 Million Private Placement
2025-11-12 iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Past events

Date Event Type
2026-11-10 Guggenheim Healthcare Innovation 2026 Conference Conference
2026-11-10 Guggenheim 3rd Annual Healthcare Innovation Conference Conference
2026-09-08 Wells Fargo 21st Healthcare Conference Conference
2026-06-04 Jefferies Global Healthcare Conference Conference

Source: https://ir.ibioinc.com/

Key facts CIK 1420720 CUSIP 451033708 13F (30d) 40 filings 33 filers Visit website Investor relations